DRKS00030784尚未招募不适用
eurfilamenT foR diffErEntiaTion Of Pseudo-relapse - TREETOP
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. RRMS with subjective disease activity. 2. capable of consent. 3. Over 18 years old
排除标准
- •1. No consent. 2. No RRMS, 3. <18 years old.
研究者
相似试验
尚未招募
Unknown
Assessment of moisturizing and recurring effect of the cosmetic cream on the whole body of age 6 months to 15 years of children using instruments and dermatologist evaluation.CTRI/2024/05/068058AOS LES LABORATOIRES
已完成
不适用
Prospective observational study of relapsed and refractory pediatric acute lymphoblastic leukemiaacute lymphoblastic leukemiaJPRN-UMIN000019878Japanese Pediatric Leukemia/Lymphoma Study Group76
招募中
不适用
A prospective observational study on relapse prevention factor in electroconvulsive therapySchizophrenia Major depressive disorder Bipolar disorderJPRN-UMIN000036585Department of Neuropsychiatry, Wakayama Medical University60
进行中（未招募）
1 期
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55
进行中（未招募）
1 期
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 20.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000012975MedDRA version: 20.0Level: LLTClassification code 10063621Term: Acute lymphoblastic leukaemia recurrentSystem Organ Class: 100000012975EUCTR2016-001991-31-FRovartis Pharma AG55